XML 125 R96.htm IDEA: XBRL DOCUMENT v3.25.4
Information about Components of Equity - Schedule of Financial Statements (Details) - Bioceres S.A [Member] - USD ($)
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Information about Components of Equity - Schedule of Financial Statements (Details) [Line Items]      
Current assets $ 19,390,689 $ 37,499,373  
Non-current assets (12,909,646) 78,742,912  
Total assets 6,481,043 116,242,285  
Current liabilities 97,284,715 47,526,407  
Non-current liabilities 238,458 14,689,742  
Total liabilities 97,523,173 62,216,149  
Total equity (91,042,130) 54,026,136  
Total liabilities and equity 6,481,043 116,242,285  
Revenues 780,952 1,422,707 $ 1,074,655
Government grants 3,412 197,519 49,185
Gross margin 784,364 1,620,226 1,123,840
Research and development expenses (223,688) (239,446) (175,737)
Selling, general and administrative expenses (2,275,441) (3,248,643) (3,287,433)
Share of profit or loss of subsidiaries (33,367,101) (3,285,724) 5,287,879
Share of profit or loss of joint ventures and associates (285) (2,592) (3,917)
Other income / (loss), net (56,484,792) 11,126 249,372
Operating loss (91,566,943) (5,145,053) 3,194,004
Financial results 2,891,781 (1,128,752) (4,327,324)
Loss before taxes (88,675,162) (6,273,805) (1,133,320)
Income tax (1,653,797) 471,416 (463,175)
Result for the year (90,328,959) (5,802,389) (1,596,495)
Revaluation of property, plant and equipment, net of tax     (434,390)
Foreign exchange differences on translation of foreign operations (5,467,311) (3,865,328) (5,182,181)
Total comprehensive result $ (95,796,270) $ (9,667,717) $ (7,213,066)